News

Top-line data, based on the 16-week primary endpoint, is anticipated early in the first quarter of 2018. Subjects were enrolled in 30 renal centres across the USA. A

The BTD designation granted by the US Food and Drug Administration (FDA) is indicated for the treatment of metastatic NSCLC patients who are growth factor receptor (EGFR) mutation-positive. It

The milestone is due to the successful completion of a screening campaign using Evotec's induced pluripotent stem cell ("iPSC")-based screening platform. This milestone has been achieved under an

The company has recruited first patient in the trial of NanoPac sterile suspension in patients with ovarian cancer. The trial will assess NanoPac’s safety and efficacy after IP

These funds will enable clinical advancement of PAN-90806, a small molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases. The additional financing,

Synthon’s three-times-a-week glatiramer acetate is a therapeutically equivalent version of the originator medicine Copaxone®* 40mg.  Synthon received regulatory clearance in all 27 EU/EEA member states involved in the

The study is assessing the efficacy and safety of anticoagulant medicine for the secondary prevention of stroke and systemic embolism in patients with a recent embolic stroke of

The FDA’s orphan designation is granted to encourage the development of potential products for rare conditions that affect less than 200,000 patients annually in the US. cGVHD is

The company raised an initial $23.1 million in June 2016. The extension of the Series C supports Visterra’s focus on its two lead product candidates, VIS410 and VIS649,